 CAMBRIDGE Mass., Aug. 30, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM for the treatment of cancer and autoimmune diseases, today announced the appointment of Jim Jogerst as chief business officer. He will oversee business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius overall corporate strategy. 